Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for GNI Group's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2160 vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, GNI Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GNI Group Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GNI Group's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where GNI Group's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNI Group (TSE:2160) has a Buyback Yield % of -7.38 as of Jul. 16, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on GNI Group and its competitors. According to the industry distribution chart, GNI Group ranks #338 out of 740 companies in the Biotechnology industry, placing it in the top 45.7%.
Is GNI Group's Buyback Yield % too high?
GNI Group's current Buyback Yield % is -7.38. Based on the distribution chart, GNI Group ranks #338 out of 740 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GNI Group has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GNI Group's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GNI Group ranks #338 out of 740 companies for Buyback Yield %. This puts GNI Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on GNI Group and its competitors. GNI Group's current Buyback Yield % is -7.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GNI Group stock overvalued right now?
Based on GuruFocus' analysis, GNI Group (TSE:2160) is currently considered Fairly Valued. The stock's GF Value™ is 円2,787.82, compared to a current price of 円2,523.00 — trading 9.5% below its estimated fair value. The current Buyback Yield % is -7.38. GNI Group's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For GNI Group (TSE:2160), the current Buyback Yield % is -7.38 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GNI Group (TSE:2160) Overvalued in 2026?
Based on GuruFocus' analysis, GNI Group stock appears to be undervalued.
The current stock price of 円2,523.00 is trading 9.5% below its estimated GF Value™ of 円2,787.82.
GuruFocus considers GNI Group to be Fairly Valued.
Key valuation signals for TSE:2160:
Buyback Yield %: -7.38
GF Value™: 円2,787.82 vs. price of 円2,523.00 (9.5% below fair value)
No single metric tells the full story. See the TSE:2160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
84GF Score
Get the complete analysis for TSE:2160
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2160 has been successfully added to your 
